Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Delayed Quote. Delayed  - 01/16 04:59:36 pm
252.2 DKK   +0.76%
01/16 LAWSUIT FOR INV : Nvo)
01/16 NOVO NORDISK A/ : - Share repurchase programme
01/13 Rosen Law Firm Announces Filing of Securities Class Action Lawsui..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
01/10/2017 01/11/2017 01/12/2017 01/13/2017 01/16/2017 Date
254(c) 255.3(c) 245.1(c) 250.3(c) 252.2(c) Last
3 383 903 3 074 090 7 488 213 4 228 437 3 493 050 Volume
-0.82% +0.51% -4.00% +2.12% +0.76% Change
More quotes
Financials ( DKK)
Sales 2016 111 798 M
EBIT 2016 48 736 M
Net income 2016 38 058 M
Finance 2016 13 702 M
Yield 2016 2,82%
Sales 2017 116 449 M
EBIT 2017 50 176 M
Net income 2017 39 392 M
Finance 2017 15 590 M
Yield 2017 3,01%
P/E ratio 2016 16,79
P/E ratio 2017 15,87
EV / Sales2016 4,42x
EV / Sales2017 4,22x
Capitalization 507 569 M
More Financials
Company
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments.The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related... 
Sector
Pharmaceuticals
Calendar
02/02Earnings Release
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
01/16 LAWSUIT FOR INVESTORS WHO LOST MONEY : Nvo)
01/16 NOVO NORDISK A/S : - Share repurchase programme
01/13 Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against No..
01/12 NOVO NORDISK A/S : An Application for the Trademark "SOLVE" Has Been Filed by No..
01/12 NOVO NORDISK A/S : Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Clas..
01/12 REPORTS ON GLUCAGON THERAPY FROM NOV : Chemical...
01/12 NOVO NORDISK A/S : Researchers Submit Patent Application, "Mating Factor Alpha P..
01/12 INVESTIGATORS AT NOVO NORDISK TARGET : ...
01/11 NOVO NORDISK A/S : Fiasp (fast-acting insulin aspart) approved in Europe
01/11 NOVO NORDISK A/S : Fiasp (fast-acting insulin aspart) approved in Europe
More news
Sector news : Pharmaceuticals - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/13DJLONDON MARKETS : FTSE 100 Continues Record Run, Rising For 14th Day In A Row
01/13 FTSE hits record highs, extends historic winning streak
01/12DJCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
01/12 Investors in big pharma, biotech look to ride out Trump storm
More sector news : Pharmaceuticals - NEC
Latest Tweets
01/13Longer term #Novo nordisk - might still be one last leg down potentially. $NV.. 
01/13Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against No.. 
More tweets
Qtime:42
News from SeekingAlpha
01/13 SANOFI : Key Threats In 2017 And Beyond
01/13 A REAL DIVIDEND GROWTH MACHINE : 2016 Portfolio Review
01/13 BIOTECHS : What The 'Trump Dump' And CVS's EpiPen Move May Mean
01/12 THE THREATS AND OPPORTUNITIES IN NAS : What Next For Allergan?
01/11 AbbVie promises to keep price hikes below 10%
Advertisement
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 279  DKK
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-1.73%72 097
JOHNSON & JOHNSON-0.53%311 773
ROCHE HOLDING LTD.2.75%204 641
PFIZER INC.0.12%197 343
NOVARTIS AG-1.48%189 749
MERCK & CO., INC.5.89%171 880
More Results